The Biotech Crossroads: Inside Sarepta's Shakeup and Vor's PivotGlobal Report·1 day ago, 04:43 AMSRPT-2.58%VOR-2.18%
US Rare Disease Biotechs Navigate Regulatory Scrutiny and Revised 2026 GuidanceGlobal Report·Aug 13 at 04:42 AMSRPT-2.58%
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)Tip Ranks·Aug 6 at 06:19 AMSRPT-2.58%SRPU0.00%
Sarepta Q2 FY26 net income turns to USD 4.89 million loss; revenue drops 34% to USD 401.25 millionPUBT·Aug 5 at 03:09 PMSRPT-2.58%SRPU0.00%
The Overlooked Summer Shakeups: Spinoffs, FDA Drama, and Insider BetsGlobal Report·Aug 4 at 04:17 AMTRIP-3.56%SRPT-2.58%
Stop Buying the AI Buzzwords and Look at Who is Actually Printing MoneyGlobal Report·Jul 31 at 04:21 AMEQIX+0.51%AZO-3.73%
Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes OverSimplywall·Jul 30 at 10:23 AMSRPT-2.58%SRPU0.00%
Tracking Specialized Equities: Fox's Roku Buyout and Key C-Suite Reshuffles Drive Idiosyncratic FlowGlobal Report·Jul 30 at 04:13 AMZTS-2.16%SRPT-2.58%
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from BrokeragesMarket Beat·Jul 30 at 01:14 AMSRPT-2.58%SRPU0.00%
